Please note that 02xl.com provides this information for the benefit of the disease community. 02xl.com is not a medical provider or health care facility and thus can neither diagnose any disease or disorder nor endorse or recommend any specific medical treatments. Patients must rely on the personal and individualized medical advice of their qualified health care professionals before seeking any information related to their particular diagnosis, cure or treatment of a condition or disorder.
Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72, 7–33 (2022).
Chen, W. et al. Cancer statistics in China, 2015. CA Cancer J. Clin. 66, 115–132 (2016).
Lee, D. Y. et al. Impact of systemic inflammation on the relationship between insulin resistance and all-cause and cancer-related mortality. Metabolism 81, 52–62 (2018).
Korniluk, A., Koper, O., Kemona, H. & Dymicka-Piekarska, V. From inflammation to cancer. Ir. J. Med. Sci. 186, 57–62 (2017).
Argiles, J. M., Lopez-Soriano, F. J. & Busquets, S. Counteracting inflammation: A promising therapy in cachexia. Crit. Rev. Oncog. 17, 253–262 (2012).
Fearon, K. C. et al. Pancreatic cancer as a model: Inflammatory mediators, acute-phase response, and cancer cachexia. World J. Surg. 23, 584–588 (1999).
Argiles, J. M. & Lopez-Soriano, F. J. Insulin and cancer (Review). Int. J. Oncol. 18, 683–687 (2001).
Tayek, J. A. A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. J. Am. Coll. Nutr. 11, 445–456 (1992).
Glicksman, A. S. & Rawson, R. W. Diabetes and altered carbohydrate metabolism in patients with cancer. Cancer 9, 1127–1134 (1956).
Dev, R., Bruera, E. & Dalal, S. Insulin resistance and body composition in cancer patients. Ann. Oncol. 29, ii18–ii26 (2018).
Fonseca, G., Farkas, J., Dora, E., von Haehling, S. & Lainscak, M. Cancer cachexia and related metabolic dysfunction. Int. J. Mol. Sci. 21, 2321 (2020).
Formiguera, X. & Canton, A. Obesity: Epidemiology and clinical aspects. Best Pract. Res. Clin. Gastroenterol. 18, 1125–1146 (2004).
Finucane, M. M. et al. National, regional, and global trends in body-mass index since 1980: Systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 377, 557–567 (2011).
Duggan, C. et al. Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J. Clin. Oncol. 29, 32–39 (2011).
Majed, B., Moreau, T., Asselain, B., Curie Institute Breast Cancer, G. Overweight, obesity and breast cancer prognosis: Optimal body size indicator cut-points. Breast Cancer Res. Treat. 115, 193–203 (2009).
Iyengar, N. M., Gucalp, A., Dannenberg, A. J. & Hudis, C. A. Obesity and cancer mechanisms: Tumor microenvironment and inflammation. J. Clin. Oncol. 34, 4270–4276 (2016).
van Kruijsdijk, R. C., van der Wall, E. & Visseren, F. L. Obesity and cancer: The role of dysfunctional adipose tissue. Cancer Epidemiol. Biomark. Prev. 18, 2569–2578 (2009).
Kershaw, E. E. & Flier, J. S. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89, 2548–2556 (2004).
Sartipy, P. & Loskutoff, D. J. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc. Natl. Acad. Sci. USA 100, 7265–7270 (2003).
Xu, H. et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112, 1821–1830 (2003).
Cancello, R. et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 54, 2277–2286 (2005).
Wang, Z. & Nakayama, T. Inflammation, a link between obesity and cardiovascular disease. Mediat. Inflamm. 2010, 535918 (2010).
Amin, M. N. et al. How the association between obesity and inflammation may lead to insulin resistance and cancer. Diabetes Metab. Syndr. 13, 1213–1224 (2019).
Guo, Q. et al. IGF-I CA19 repeat polymorphisms and cancer risk: A meta-analysis. Int. J. Clin. Exp. Med. 8, 20596–20602 (2015).
Leung, K. C., Doyle, N., Ballesteros, M., Waters, M. J. & Ho, K. K. Insulin regulation of human hepatic growth hormone receptors: Divergent effects on biosynthesis and surface translocation. J. Clin. Endocrinol. Metab. 85, 4712–4720 (2000).
Pierce, B. L. et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J. Clin. Oncol. 27, 3437–3444 (2009).
Albuquerque, K. V. et al. Pre-treatment serum levels of tumour markers in metastatic breast cancer: A prospective assessment of their role in predicting response to therapy and survival. Eur. J. Surg. Oncol. 21, 504–509 (1995).
Gunter, M. J. et al. Circulating adipokines and inflammatory markers and postmenopausal breast cancer risk. J. Natl. Cancer Inst. 107, djv169 (2015).
Zhou, L. et al. A retrospective propensity score matched study of the preoperative C-reactive protein to albumin ratio and prognosis in patients with resectable non-metastatic breast cancer. Med. Sci. Monit. 25, 4342–4352 (2019).
Chen, F. et al. Prognostic significance of neutrophil-to-lymphocyte ratio and C-reactive protein/albumin ratio in luminal breast cancers with HER2-negativity. Front. Oncol. 12, 845935 (2022).
Zhang, X. et al. The nutrition-inflammation marker enhances prognostic value to ECOG performance status in overweight or obese patients with cancer. JPEN J. Parenter Enter. Nutr. 47, 109–119 (2022).
Okugawa, Y. et al. Lymphocyte-to-C-reactive protein ratio and score are clinically feasible nutrition-inflammation markers of outcome in patients with gastric cancer. Clin. Nutr. 39, 1209–1217 (2020).
Okugawa, Y. et al. Lymphocyte-C-reactive protein ratio as promising new marker for predicting surgical and oncological outcomes in colorectal cancer. Ann. Surg. 272, 342–351 (2020).
Goodwin, P. J. et al. Fasting insulin and outcome in early-stage breast cancer: Results of a prospective cohort study. J. Clin. Oncol. 20, 42–51 (2002).
Pasanisi, P. et al. Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int. J. Cancer. 119, 236–238 (2006).
DeFronzo, R. A., Tobin, J. D. & Andres, R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am. J. Physiol. 237, E214-223 (1979).
Fritz, J. et al. The triglyceride-glucose index as a measure of insulin resistance and risk of obesity-related cancers. Int. J. Epidemiol. 49, 193–204 (2020).
Kheirollahi, A. et al. Evaluation of lipid ratios and triglyceride-glucose index as risk markers of insulin resistance in Iranian polycystic ovary syndrome women. Lipids Health Dis. 19, 235 (2020).
Zhou, M. et al. The triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio as a predictor of insulin resistance but not of beta cell function in a Chinese population with different glucose tolerance status. Lipids Health Dis. 15, 104 (2016).
Rose, D. P., Komninou, D. & Stephenson, G. D. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes. Rev. 5, 153–165 (2004).
Kern, P. A., Ranganathan, S., Li, C., Wood, L. & Ranganathan, G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 280, E745-751 (2001).
Gallagher, E. J. & LeRoith, D. Insulin, insulin resistance, obesity, and cancer. Curr. Diabetes Rep. 10, 93–100 (2010).
Lorincz, A. M. & Sukumar, S. Molecular links between obesity and breast cancer. Endocr. Relat. Cancer. 13, 279–292 (2006).
Ni, H. H. et al. Combining pre- and postoperative lymphocyte-C-Reactive protein ratios can better predict hepatocellular carcinoma prognosis after partial hepatectomy. J. Inflamm. Res. 15, 2229–2241 (2022).
Liu, Y. L., Qian, H. X., Qin, L., Zhou, X. J. & Zhang, B. Serum LDL-C and LDL-C/HDL-C ratio are positively correlated to lymph node stages in males with colorectal cancer. Hepatogastroenterology. 58, 383–387 (2011).
Notarnicola, M. et al. Serum lipid profile in colorectal cancer patients with and without synchronous distant metastases. Oncology 68, 371–374 (2005).
Ma, M. Z., Yuan, S. Q., Chen, Y. M. & Zhou, Z. W. Preoperative apolipoprotein B/apolipoprotein A1 ratio: A novel prognostic factor for gastric cancer. Onco Targets Ther. 11, 2169–2176 (2018).
Dai, D. et al. Pretreatment TG/HDL-C ratio is superior to triacylglycerol level as an independent prognostic factor for the survival of triple negative breast cancer patients. J. Cancer. 7, 1747–1754 (2016).
Luo, Y. Z. et al. Pretreatment triglycerides-to-high density lipoprotein cholesterol ratio in postmenopausal women with endometrial cancer. Kaohsiung J. Med. Sci. 35, 303–309 (2019).
Sun, H. et al. Triglyceride-to-high density lipoprotein cholesterol ratio predicts clinical outcomes in patients with gastric cancer. J. Cancer. 10, 6829–6836 (2019).
McNelis, J. C. & Olefsky, J. M. Macrophages, immunity, and metabolic disease. Immunity 41, 36–48 (2014).
Matsuzawa, Y., Funahashi, T. & Nakamura, T. Molecular mechanism of metabolic syndrome X: Contribution of adipocytokines adipocyte-derived bioactive substances. Ann. N. Y. Acad. Sci. 892, 146–154 (1999).
Fischer, S. et al. Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass. Acta Diabetol. 39, 105–110 (2002).
Wauters, M. et al. Leptin levels in type 2 diabetes: Associations with measures of insulin resistance and insulin secretion. Horm. Metab. Res. 35, 92–96 (2003).
Leyva, F. et al. Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. Arterioscler. Thromb. Vasc. Biol. 18, 928–933 (1998).
Hotamisligil, G. S., Arner, P., Caro, J. F., Atkinson, R. L. & Spiegelman, B. M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Invest. 95, 2409–2415 (1995).
Aldhahi, W. & Hamdy, O. Adipokines, inflammation, and the endothelium in diabetes. Curr. Diabates Rep. 3, 293–298 (2003).
Ibrahim, M. M. Subcutaneous and visceral adipose tissue: Structural and functional differences. Obes. Rev. 11, 11–18 (2010).
Sonnenberg, G. E., Krakower, G. R. & Kissebah, A. H. A novel pathway to the manifestations of metabolic syndrome. Obes. Res. 12, 180–186 (2004).
Share your experience. Everybody’s experience of Overweight & Obesity is different. There are many ways to address people’s lived experience of Overweight & Obesity, that must work for the individual. Sharing your story can help change perspectives and inspire others who may feel alone and unrepresented. You can also hear from other people about their experience of Overweight & Obesity.
Thanks for being there: We need your help. The 02xl Overweigt & Obesity
Community continues to grow but revenues have never been harder to maintain.
With the rise of Ad Blockers, and Facebook - our traditional revenue sources via quality network advertising continues to decline. And unlike so many other news sites, we don't have a paywall - with those annoying usernames and passwords. Our news coverage takes time and effort to publish 365 days a year. If you find our news sites informative and useful then please consider becoming a regular supporter or for now make a one off contribution.